medicina59巻7号

2022年06月発行

特集 抗菌薬の使い方—敵はコロナだけにあらず！ 今こそ基本に立ち返る 抗菌薬を処方する前に知るべきこと

PK/PDを理解する

著者： 枦秀樹¹

所属機関： ¹東京ベイ・浦安市川医療センター薬剤室

ページ範囲：P.1004 - P.1011

Point
◎抗菌薬のPDはin vitroでの抗菌薬の濃度と細菌の増殖抑制効果の関係である最小発育阻止濃度（MIC）で代替される．
◎抗菌薬の投与量を標的臓器における濃度に変換し，起因菌の感受性を組み合わせれば，患者個々の感染症治療の最適化につなげることができる．
◎抗菌薬の効果的なPDを得るためにはPKの概念を考慮して投与設計を行うことが必要である．
◎PKは複合要因により影響を受ける．要因として主に患者背景と病態がある．それぞれの場合の変動を考慮する必要がある．

参考文献

1）Rybak MJ, et al：Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections；A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 77：835-864, 2020

2）Guilhaumou R, et al：Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics（Societe Francaise de Pharmacologie et Therapeutique-SFPT）and the French Society of Anaesthesia and Intensive Care Medicine（Societe Francaise d'Anesthesie et Reanimation-SFAR）. Crit Care 23：104, 2019

3）Verhave JC, et al：Estimation of renal function in subjects with normal serum creatinine levels；Influence of age and body mass index. Am J Kidney Dis 46：233-241, 2005

4）Brill MJ, et al：Reduced subcutaneous tissue distribution of cefazolin in morbidly obese versus non-obese patients determined using clinical microdialysis. J Antimicrob Chemother 69：715-723, 2014

5）Alobaid AS, et al：What is the effect of obesity on piperacillin and meropenem trough concentrations in critically ill patients? J Antimicrob Chemother 71：696-702, 2016

6）Sturm AW, et al：Pharmacokinetic analysis of piperacillin administered with tazobactam in critically ill, morbidly obese surgical patients. Pharmacotherapy 34：28-35, 2014

7）Udy AA, et al：Subtherapeutic initial beta-lactam concentrations in select critically ill patients；Association between augmented renal clearance and low trough drug concentrations. Chest 142：30-39, 2012

8）Roberts JA, Lipman J：Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility. Crit Care Med 41：489-495, 2013

9）Ross AL, et al：Evaluation of extended interval dosing aminoglycosides in the morbidly obese population. Adv Pharmacol Sci 2013：194389, 2013

10）Pea F：Plasma pharmacokinetics of antimicrobial agents in critically ill patients. Curr Clin Pharmacol 8：5-12, 2013